RapidAI, a global leader in AI-driven medical imaging analysis and coordinated care, has received FDA 510(k) clearance for Lumina 3D™. This is the first automated 3D imaging reconstruction solution designed to replace manual processes with AI-driven technology. It aims to enhance efficiency and accuracy in neuroradiology.
Generating high-quality 3D images within minutes of a CTA scan represents a significant step forward in medical imaging. Radiologists often require detailed vascular imaging for accurate diagnoses, but challenges such as image quality, availability, time constraints, and costs create obstacles.
With increasing Head and Neck CTA volumes and a shortage of skilled professionals, Lumina 3D™ helps address these issues by delivering near real-time 3D imaging with vessel segmentation and bone removal.
This solution improves anomaly detection, streamlines workflows for neuroradiologists, and enhances patient outcomes.
Manual CTA reconstructions typically take significant time, sometimes delaying critical diagnoses. Lumina 3D reduces this process to minutes, functioning in real-time and on a large scale to ensure continuous availability for hospitals of all sizes.
Designed for speed, accuracy, and efficiency, it alleviates the workload for radiologists and imaging technologists, increasing productivity while accelerating diagnosis and treatment processes. This contributes to improved patient care and hospital efficiency.
Lumina 3D is hosted on Rapid Edge Cloud, the only industry platform offering flexible deployment options, including on-premises, cloud, or hybrid infrastructures. This ensures high speed, security, and scalability, providing a reliable solution for healthcare institutions seeking advanced AI-driven imaging support.
It aims to empower clinicians with faster and more reliable decision-making tools. Lumina 3D builds upon RapidAI’s expertise in neuroscience, redefining AI-powered 3D imaging and paving the way for future innovations in medical imaging technology.
